Risk Stratification and Treatment Selection in HER2+ Breast Cancer: The Current Treatment Landscape and NCCN Guideline Recommendations
Paolo Tarantino, MD, discusses risk factors in early breast cancer, NCCN guideline-recommended therapies, and the transformative impact of HER2-targeted treatments over the past decade.
EP: 1.Overview of HER2-Targeting Agents in Breast Cancer and Treatment Selection Approaches
EP: 2.APHINITY Trial: Pertuzumab for Patients with HER2+ Breast Cancer
EP: 3.KATHERINE: Adjuvant T-DM1 vs Trastuzumab for Residual Invasive HER2+ Breast Cancer
EP: 4.Exciting Developments in HER2+ Breast Cancer
EP: 5.Current Approaches to Treatment Sequencing in HER2+ Breast Cancer
EP: 6.Unmet Needs and Future Directions in HER2+ Breast Cancer
EP: 7.Risk Stratification and Treatment Selection in HER2+ Breast Cancer: The Current Treatment Landscape and NCCN Guideline Recommendations
EP: 8.Long-Term Pertuzumab Outcomes in HER2+ Breast Cancer: Insights from APHINITY 8-Year Data and NeoSphere Pooled Analysis
EP: 9.KATHERINE Trial: Long-Term Outcomes of T-DM1 vs Trastuzumab in HER2+ Breast Cancer with Residual Disease
EP: 10.The Expanding Treatment Armamentarium and Clinical Decision Making: ExteNET, DestinyBREAST-05, HER2CLIMB, and Other Emerging Trials
EP: 11.Unmet Needs and Future Directions in HER2+ Breast Cancer Management
Video content above is prompted by the following:
- Discuss the risk factors and clinical characteristics that define high-risk early breast cancer, such as tumor size, nodal status, hormone receptor status, and residual disease after neoadjuvant therapy.
- How should clinicians approach risk stratification in early breast cancer to identify high-risk patients who may benefit from more aggressive treatment?
- Please provide a brief overview of treatment options in HER2+ breast cancer.
- Please highlight the NCCN guideline recommendations for managing early breast cancer, particularly Category 1 preferred options.
- How have the available HER2-targeted therapies changed the treatment landscape for patients with HER2+ breast cancer over the past decade or so?
- What are the key factors you consider when selecting an appropriate HER2-targeted therapy for your patients with HER2+ breast cancer?
- How do you approach the sequencing and combinations of HER2-targeted agents in the adjuvant, neoadjuvant, and metastatic settings?
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
ADCs Demonstrate Superiority Vs Chemotherapy in Recurrent Breast Cancer
August 20th 2024During a Case-Based Roundtable® event, Reshma Mahtani, DO, discussed the importance of data from the TROPiCS-02 and TROPION-Breast01 trials of antibody-drug conjugates in patients with hormone receptor positive metastatic breast cancer.
Read More
